Functional enrichment analysis suggested that berberine exerts its anti-HCC effects mainly by interfering with cell cycle progression, chromosome segregation, and the p53 signaling pathway, indicating that its therapeutic effect is achieved through synergistic targeting of AURKA and CDK1. Here, CDK1 is linked to hepatocellular carcinoma.